targeted therapy

Tag:targeted therapy

Advanced, HER2 Negative Breast Cancer Treatment

Different breast cancers behave in different ways, which necessitates separate treatment guidelines to address the individual characteristics of specific types of cancer. As knowledge evolves, treatment guidelines are updated to reflect up-to-date information about breast cancer. Recently, the American Society of Clinical Oncology (ASCO) published guidelines on the use of chemotherapy and targeted therapy in the treatment of patients with advanced, HER2 negative breast cancer.

What is HER2 Negative Breast Cancer?

HER2, or human epidermal growth factor receptor 2, is a protein that the human body develops to help regulate reproduction of the cells. Sometimes the gene responsible for developing this protein will over-replicate itself, which can result in overproduction of HER2. […]

By | November 17, 2014|Categories: Oncology|Tags: , |0 Comments

Breast Cancer Genomics

The availability of molecular information on breast cancer genomics is rapidly expanding. Patients who are newly diagnosed with breast cancer can easily be overwhelmed by volumes of information in a very short period of time. The good news is that all of the information available is meant to guide personal decisions for cancer management so that we use biology and science for real-life choices. Knowledge is power.

Next Generation of Breast Cancer | Dr Kapoor

The Next Generation of Breast Cancer

Join Dr. Kapoor on Thursday, October 9 from 6-7:30 pm in Santa Ana for her talk on advances in screening, surveillance and […]

Kadcyla and New Targeted Breast Cancer Drugs

HER2 positive breast cancer | BreastlinkKadcyla, approved by the U.S. Food and Drug Administration (FDA) in February 2013, is one of the latest advancements to improve our ability to treat breast cancer. Although Kadcyla was only approved for a specific population of breast cancer patients (HER2 positive breast cancer that has spread to other parts of the body (metastatic breast cancer)), it fits into a larger story that is fundamentally changing how we treat many types of breast cancer.

Kadcyla is the fourth drug approved by the FDA to specifically target the HER2 protein. As HER2-positive breast cancer tends to be more aggressive […]

By | February 21, 2014|Categories: Oncology|Tags: |2 Comments

Review of the 2013 SABCS

Bevacizumab | 2013 SABCS | BreastlinkThe San Antonio Breast Cancer Symposium (SABCS) is an annual international conference directed towards academicians, private physicians and researchers with more than 7,000 in attendance from 90 countries. The purpose of the symposium is to relay breaking news, trial updates, advances in biology and practice-changing guidelines in breast cancer care and management.

Breastlink sends a team of physicians and researchers to SABCS every year to gather critical updates and research advances. We then disseminate the results to patients, referring physicians and the Breastlink medical team. Last year, for example, the results of the ATLAS trial delivered at the 2012 […]

By | February 3, 2014|Categories: Cancer News, Cancer Research|Tags: , |0 Comments

SABCS 2013 – Anastrozole

The 2013 San Antonio Breast Cancer Symposium was an engaging and invigorating event – I look forward to sharing what I have learned with colleagues and patients. If you have any specific questions you would like me to address about this year’s Symposium please feel free to leave a comment to this blog post or contact my office.

Dr. Nimmi Kapoor and I will also be sharing our observations from this year’s San Antonio Breast Cancer Symposium in a series of community lectures in January. We will share details when they are confirmed.

Here are a few observations from the plenary sessions I attended on Thursday and Friday.

Anastrozole May Provide New Option […]

By | December 17, 2013|Categories: Cancer Research, Oncology|Tags: , |0 Comments

Adding Perjeta to the Treatment of HER2-Positive Tumors Prior to Surgery

perjetaPertuzumab (Perjeta) became the first drug to ever be approved by the FDA for use prior to surgery for non-metastatic breast cancer on September 30, 2013. This development further signals a paradigm shift away from chemotherapy and towards targeted therapy – specifically in the now increasingly target-rich environment of HER2-positive breast cancer.

What is Perjeta?

Pertuzumab is a monoclonal antibody, which works by preventing a molecular interaction between the HER2 receptor and other related receptors on the breast cancer cell’s surface. We’ve known about the effectiveness of pertuzumab based on a prior trial with over 800 patients (CLEOPATRA).

What is HER2 positive <a href=[…]

By | November 13, 2013|Categories: Oncology|Tags: |0 Comments
Load More Posts